Interim results of first-ever global survey show people with type 2 diabetes underestimate their cardiovascular risk
- Details
- Category: Novo Nordisk
Today the International Diabetes Federation (IDF) presented the interim results of the first ever multi-country online survey on CVD risk awareness and knowledge among people living with type 2 diabetes, indicating low levels of awareness and limited dialogue between patients and healthcare professionals. The global survey - Taking Diabetes to Heart - developed in partnership with Novo Nordisk, runs until March 2018 and is open to all people with type 2 diabetes.
Bristol-Myers Squibb and Pfizer Alliance urge people to 'Tune in to AFib, Take Note of Stroke Risk'
- Details
- Category: Bristol-Myers Squibb
The Bristol-Myers Squibb and Pfizer Alliance, the National Stroke Association and iHeartMedia today launched 'Tune in to AFib, Take Note of Stroke Risk' to educate the estimated nearly seven million Americans in 2017 living with atrial fibrillation (AFib) not caused by a heart valve problem about their increased risk of stroke.
Pfizer enters into agreement to develop and commercialize CRESEMBA® (isavuconazole) in China and Asia Pacific region
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) and Basilea Pharmaceutica Ltd. (SIX:BSLN), an international biopharmaceutical company specializing in the research and development of anti-infective and oncological medicines, today announced they have entered into an agreement whereby Pfizer will be granted the exclusive development and commercialization rights in China and several countries in the Asia Pacific region to CRESEMBA (isavuconazole).
Novartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab (AMG334) in migraine prevention
- Details
- Category: Novartis
Novartis today announced that the New England Journal of Medicine (NEJM) published positive results from the six-month Phase III STRIVE study evaluating erenumab in the prevention of episodic migraine (defined in STRIVE as 4 to 14 migraine days per month)[1]. Erenumab delivered clinically meaningful and statistically significant differences from placebo for all primary and secondary endpoints including those measured by the novel, validated Migraine Physical Function Impact Diary (MPFID)[2].
Bristol-Myers Squibb awards "Golden Tickets" for LabCentral to Neutrolis, Remora Therapeutics
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today announced that Neutrolis and Remora Therapeutics are the winners of Bristol-Myers Squibb's 2017 Golden Tickets for LabCentral. As a platinum sponsor of LabCentral, Bristol-Myers Squibb can select up to two innovative life-sciences and biotech startup companies per year of active sponsorship for "Golden Tickets,"
AstraZeneca and Chinese Future Industry Investment Fund establish joint venture to develop new medicines in China
- Details
- Category: AstraZeneca
AstraZeneca today announced a strategic joint venture with the Chinese Future Industry Investment Fund (FIIF) to form an equally-owned, stand-alone company in China to discover, develop and commercialise potential new medicines to help meet unmet needs globally, and to bring innovative new medicines to patients in China faster.
Novartis' Ultibro® Breezhaler® significantly improved COPD patients' lung function after direct switch from Seretide®
- Details
- Category: Novartis
Novartis today announced positive results from the FLASH** study examining the safety and efficacy of directly switching chronic obstructive pulmonary disease (COPD) patients from Seretide® (salmeterol/fluticasone) 50/500 mcg to Ultibro® Breezhaler® (indacaterol/glycopyrronium) 110/50 mcg[1]. The study met the primary endpoint demonstrating that switching patients to Ultibro Breezhaler resulted in significantly improved lung function (trough FEV1)[1].
More Pharma News ...
- GSK submits landmark IMPACT data to US regulatory authority to support expanded label for Trelegy Ellipta
- Boehringer Ingelheim makes many of its best molecules openly available to the scientific community via opnMe.com to unlock their full potential
- Roche to acquire Viewics, Inc. to provide data-driven lab business analytics and add further digital capabilities along the laboratory value chain
- Novartis, ASCP and ACS join forces to fight cancer in Ethiopia, Uganda and Tanzania
- Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer
- Pfizer receives FDA approval for SUTENT® (sunitinib malate) as first and only adjuvant treatment for adult patients at high risk of recurrent renal cell carcinoma
- Fasenra (benralizumab) receives US FDA approval for severe eosinophilic asthma